Atlas Trials

Feasibility Study on the Use of Redormin®500 on Day-time Cognition

Clinical trial NCT05684523 · COMPLETED

Trial details

NCT number
NCT05684523
Sponsor
Max Zeller Soehne AG
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
Sleep Disorders, Circadian RhythmCognitive Dysfunction
Start date
2023-03-01
Primary completion
2023-12-20
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.